Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case

  • Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & Johnson and Takeda provide significant milestone payments, royalties, and potential for $500M–$1B annual revenue by 2030, I'd speculate. A robust cash position and a promising preclinical obesity program enhance Protagonist's strategic value and acquisition appeal.